About
Addressing the critical needs of immunocompromised patients
Company Overview
Aicuris is at the forefront of developing innovative therapies to protect individuals with weakened immune systems from life-threatening infections. We are addressing the growing global challenge of immunodeficiency by delivering breakthrough treatments that make a tangible difference for patients in need.
Our profound expertise and track-record of transforming scientific innovation into impactful therapies has enabled us to build a robust pipeline, including the late-stage candidate pritelivir, which targets recurrent and resistant HSV infections in vulnerable patient populations.
At Aicuris, we combine deep scientific knowledge with a patient-first mindset, striving to redefine the future of infection prevention and treatment.

Team
Aicuris is led by an experienced management team. At the company’s heart is a group of scientists who bring extensive international experience in drug discovery and development, and know-how gained from working at both large and small pharmaceutical companies.
Executive Board

LARRY EDWARDS
Chief Executive Officer (CEO)

SABRINA KUTTRUFF-COQUI, PHD
Chief Financial Officer (CFO)

CYNTHIA WAT, MD
Chief Medical Officer

JACQUES DUMAS, PHD
Chief Scientific Officer
Leadership Team

ILONA ARNOLD
Vice President Finance Operations

ALEXANDER BIRKMANN, PHD
Vice President Virology and
HSV Platform

HELMUT BUSCHMANN, PHD
Vice President CMC & IP

DANIELA BOSHOVEN
Director Human Resources

THOMAS DESZERI
Director IT

DILRUWAN CHAMINDA HERATH, MD
Senior Director Clinical Development

GERRIT VAN DYKEN
Senior Director Legal/
General Counsel

BERNHARD IRLINGER, PHD
Director Quality Assurance

DIRK KROPEIT, MD
Senior Director Early Clinical Development

KENNETH LAWRENCE
Senior Vice President Medical Affairs

BERNHARD LESCH
Director Medicial Chemistry

PETER LISCHKA, PHD
Senior Director Virology

ALESSANDRA MARINI, MD
Medical Director

KATHARINA NOTHELFER, PHD
Director Strategic Communication

THOMAS OUELLETTE
Vice President Operations

XAVIER PRUGNARD
Vice President Regulatory Affairs

MELANIE SUMNER
Project Director

ANDREAS URBAN, PHD
Senior Director Virology
Supervisory Board

STEFAN OSCHMANN, PHD
Chairman

HELMUT JEGGLE
Founder and Managing Partner
Salvia GmbH

PROF. HELGA RÜBSAMEN‐SCHAEFF, PHD
Founding CEO of Aicuris

SEAN MARETT
Former CBO and CCO
BioNTech SE